The discovery of two unique molecular targets known to speed skin-cancer growth has researchers excited that they might soon understand and develop genetic therapies geared toward some of medicine’s most untreatable melanomas.
Jeffrey A. Sosman, MD
A Tennessee cancer research center’s discovery of two unique molecular targets known to speed skin-cancer growth has researchers excited that they might soon understand and develop genetic therapies geared toward some of medicine’s most untreatable melanomas.
According to researchers at the Vanderbilt-Ingram Cancer Center in Nashville, about 35 percent of all skin cancers are pan-negative, meaning they lack discernible driver mutations in the genesBRAF,NRAS,KIT,GNAQ, andGNA11.
Discovering erroneous fusions of two or more genes that generate abnormal proteins and lead to cancer-cell growth is critical to developing successful therapies, according to Jeffrey A. Sosman, MD, professor of medicine at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.
“There is immense value in identifying novel mutations in untreatable cancers because many of them are clinically relevant, which means they may be sensitive to drugs that are either being developed or are already FDA approved,” Sosman said.
William Pao, MD, PhD, a physician-scientist at Vanderbilt-Ingram Cancer Center, coauthored this study with Sosman. The research team found, in one cancer patient’s melanoma sample, a fusion between two genes,PAPSS1andBRAF, which they called PAPSS1-BRAF. They identified a second novel BRAF fusion, called TRIM24-BRAF, after evaluating melanomas from another 51 patients, 24 of whom were pan-negative, according to Sosman.
Further studies revealed that both BRAF fusions activated the MAPK signaling pathway. They treated these BRAF fusion-bearing cells with the BRAF inhibitor vemurafenib or with trametinib, a drug that inhibits MEK, a protein in the MAPK signaling.
They found that signaling induced by the BRAF fusions was not responsive to vemurafenib, but could be inhibited by trametinib. This led the researchers to suggest that the novel fusions they identified could produce melanoma cells sensitive to MEK inhibitors, according to Sosman.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
July 16th 2024During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.
Read More